{"url_path":"/sec/clyd/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/2094256/0001104659-26-070999-index.html","accession_number":"0001104659-26-070999","cik":"0002094256","ticker":"CLYD","issuer_name":"BEACON TOPCO, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2094256/0001104659-26-070999-index.html","primary_entity_key":"0002094256","primary_entity_name":"BEACON TOPCO, INC."},"word_count":367,"has_tables":true,"body_markdown":"Item 2.       Management’s Discussion and Analysis of Financial Condition and Results of Operations.\n\nWe are a Delaware corporation formed on September 24, 2025 as a wholly-owned subsidiary of Barinthus Biotherapeutics plc (“Barinthus Bio”) for purposes of consummating a business combination (the “Transactions”) with Barinthus Bio and Clywedog Therapeutics, Inc., a Delaware corporation (“Clywedog”). We have one wholly-owned direct subsidiary, Cdog Merger Sub, Inc. (“Merger Sub”), which is a Delaware corporation. We have not commenced operations and have not engaged in any significant activities other than those related to our formation from our incorporation on September 24, 2025 through March 31, 2026.\n\nOn September 29, 2025, we entered into an Agreement and Plan of Merger (the “Original Merger Agreement”) with Barinthus Bio, Merger Sub, and Clywedog, as amended by that certain Amendment to the Original Merger Agreement, dated as of February 22, 2026 (such amendment, the “Merger Agreement Amendment” and, together with the Original Merger Agreement, as it may be further amended or modified from time to time, the “Merger Agreement”), pursuant to which (i) we will acquire all of the outstanding share capital of Barinthus Bio via a scheme of arrangement in accordance with Part 26 of the United Kingdom Companies Act 2006, and (ii) Merger Sub will merge with and into Clywedog, with Clywedog surviving as our wholly-owned subsidiary. Upon closing, Barinthus Bio shareholders are expected to own approximately 34% and Clywedog stockholders approximately 66% of our outstanding capital stock on a fully diluted basis, based on the respective capitalizations of Barinthus Bio and Clywedog as of the date the parties entered into the Merger Agreement. The Transactions have been unanimously approved by the boards of directors of each of Barinthus Bio and Clywedog.\n\nOn April 22, 2026, the United States Securities and Exchange Commission (the “SEC”) declared effective our Registration Statement on Form S-4, as amended, to register shares of our common stock, par value $0.0001 per share, that will be issued in connection with the Transactions.\n\nAt the closing of the Transactions, our shares of common stock will be listed on the Nasdaq Stock Market under the ticker symbol “CLYD,” and we will be renamed “Clywedog Therapeutics Holdings, Inc.”\n\n​\n\n10\n\n[Table of Contents](#TOC)"}